Bernd Liedert

Bernd Liedert is an accomplished leader in the field of clinical development for biosimilars, with extensive experience spanning over two decades in both industry and regulatory roles. From June 2014 to December 2019, Bernd served as Senior Director of Clinical Development Biosimilars at Boehringer Ingelheim, overseeing biosimilar monoclonal antibodies throughout their development phases. Currently, Bernd is the Head of Clinical Development Biosimilars at Sandoz Biopharmaceutical, leading a team dedicated to clinical biosimilar development across various therapeutic areas. Prior consulting experience at the FORUM Institute for Management involved sharing expertise with industry executives and regulators. Bernd's early career included roles as Senior Assessor and Deputy Head of Section at the Paul-Ehrlich Institute and Director at Merck KGaA, where responsibilities included guiding regulatory compliance and leading the development of immunopharmacology projects. Bernd has also held a research director position at the University Essen's West German Cancer Center, specializing in oncological and neurological pharmacotherapy.